Alessandro Passardi
Overview
Explore the profile of Alessandro Passardi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
1539
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Passardi A, Gibbons D, Scanu A, Dhar S
Front Oncol
. 2025 Mar;
15:1566681.
PMID: 40040718
No abstract available.
2.
Signorelli C, Calegari M, Anghelone A, Passardi A, Frassineti G, Bittoni A, et al.
Curr Oncol
. 2024 Dec;
31(12):7793-7808.
PMID: 39727697
Background: There is ongoing discussion around the optimal course of treatment for metastatic colorectal cancer (mCRC) following the second line. Trifluridine/tipiracil (T) and regorafenib (R) have been the mainstay of...
3.
Molinari C, Marisi G, Laliotis G, Spickard E, Rapposelli I, Petracci E, et al.
Sci Rep
. 2024 Nov;
14(1):29536.
PMID: 39604448
Post-neoadjuvant therapy (post-NAT) and post-surgical circulating tumor DNA (ctDNA) risk stratification may enhance the management of patients with locally advanced rectal cancer (LARC). In this study, we assessed the prognostic...
4.
Savoia F, Medri M, Passardi A, Melandri D, Stanganelli I
Dermatol Reports
. 2024 Nov;
16(3):9872.
PMID: 39583048
Reticulate pigmentary disorders can be classified into inherited or acquired and cutaneous drug- induced reticulate hyperpigmentation belongs to this last group. The list of the drugs involved is constantly increasing...
5.
Moretto R, Rossini D, Murgioni S, Ciraci P, Nasca V, Germani M, et al.
JCO Precis Oncol
. 2024 Nov;
8:e2400329.
PMID: 39509668
Purpose: KRASG12D mutation (mut) occurs in about 10%-12% of metastatic colorectal cancer (mCRC). Recently, novel KRASG12D inhibitors have been developed and are currently under investigation in phase I/II clinical trials...
6.
Provenzano L, Gwee Y, Conca V, Lonardi S, Bozzarelli S, Tamburini E, et al.
Ther Adv Med Oncol
. 2024 Nov;
16:17588359241289517.
PMID: 39502404
Background: Ascites is common in advanced gastrointestinal cancers with peritoneal metastases (PM) and negatively impacts patient survival. No study to date has specifically evaluated the relationship between ascites, PM and...
7.
Matteucci L, Sullo F, Gallio C, Esposito L, Muratore M, Rapposelli I, et al.
Int J Mol Sci
. 2024 Oct;
25(20).
PMID: 39456850
The efficacy and cost-effectiveness of Multigene Panel Next-Generation Sequencing (NGS) in directing patients towards genomically matched therapies remain uncertain. This study investigated metastatic colorectal cancer (mCRC) patients who underwent NGS...
8.
Granato A, Pancisi E, Piccinini C, Stefanelli M, Pignatta S, Soldati V, et al.
Cytotherapy
. 2024 Jul;
26(12):1547-1555.
PMID: 39046388
Background Aims: Dendritic cells (DCs) are professional antigen-presenting cells of the mammalian immune system. Ex vivo differentiated DCs represent a unique Advanced Therapy Medicinal Product (ATMP), used in several clinical...
9.
Passardi A, Marisi G, Ulivi P
Cancers (Basel)
. 2024 Jun;
16(12).
PMID: 38927896
Colorectal cancer (CRC) ranks third in frequency among cancers diagnosed in males and second in females [...].
10.
Antoniotti C, Rossini D, Pietrantonio F, Salvatore L, Lonardi S, Tamberi S, et al.
J Clin Oncol
. 2024 Jun;
42(22):2637-2644.
PMID: 38865678
JCO We report 4-year results of the phase II randomized AtezoTRIBE study. Eligible patients with metastatic colorectal cancer (mCRC) received first-line fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI)/bevacizumab (control group, n...